157 related articles for article (PubMed ID: 36419077)
21. Lymphadenectomy in ovarian cancer: standard of care or unnecessary risk.
Trimbos JB
Curr Opin Oncol; 2011 Sep; 23(5):507-11. PubMed ID: 21602676
[TBL] [Abstract][Full Text] [Related]
22. Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.
Paik ES; Shim M; Choi HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
Gynecol Oncol; 2016 Nov; 143(2):252-257. PubMed ID: 27567053
[TBL] [Abstract][Full Text] [Related]
23. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
Bizzarri N; du Bois A; Fruscio R; De Felice F; De Iaco P; Casarin J; Vizza E; Chiantera V; Corrado G; Cianci S; Magni S; Ferrari D; Giuliani D; Harter P; Ataseven B; Bommert M; Perrone AM; Scambia G; Fagotti A
Gynecol Oncol; 2021 Jan; 160(1):56-63. PubMed ID: 33168305
[TBL] [Abstract][Full Text] [Related]
24. Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis.
Fan Y; Zhang YF; Wang MY; Mu Y; Mo SP; Li JK
Gynecol Oncol; 2021 Sep; 162(3):797-803. PubMed ID: 34119365
[TBL] [Abstract][Full Text] [Related]
25. The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis.
Zhou J; Shan G; Chen Y
Jpn J Clin Oncol; 2016 Aug; 46(8):718-26. PubMed ID: 27272175
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of systematic lymphadenectomy in patients with ovarian cancer: A systematic review and meta-analysis.
AlMahdy AM; Elassall GM; Abdelbadee AY; Abd-Elkariem AY; Atef F; Ahmed IA; Sayed EG; Salah MA; Ali AK; Ragab EY; Abd Elazeem HAS; Saad MM; Shazly SA;
Eur J Obstet Gynecol Reprod Biol; 2021 Dec; 267():179-185. PubMed ID: 34814044
[TBL] [Abstract][Full Text] [Related]
27. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies.
Gao J; Yang X; Zhang Y
Jpn J Clin Oncol; 2015 Jan; 45(1):49-60. PubMed ID: 25387732
[TBL] [Abstract][Full Text] [Related]
28. The impact of lymphadenectomy on ovarian clear cell carcinoma: a systematic review and meta-analysis.
Liu Y; Geng F; Zhang H; Xue J; Chu R
World J Surg Oncol; 2024 Jan; 22(1):37. PubMed ID: 38287354
[TBL] [Abstract][Full Text] [Related]
29. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Lawrie TA; Rabbie R; Thoma C; Morrison J
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
[TBL] [Abstract][Full Text] [Related]
30. Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.
Lawal AO; Musekiwa A; Grobler L
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD009620. PubMed ID: 23740789
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Winter-Roach BA; Kitchener HC; Dickinson HO
Cochrane Database Syst Rev; 2009 Jul; (3):CD004706. PubMed ID: 19588360
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Lawrie TA; Winter-Roach BA; Heus P; Kitchener HC
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004706. PubMed ID: 26676202
[TBL] [Abstract][Full Text] [Related]
33. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.
Harter P; Sehouli J; Lorusso D; Reuss A; Vergote I; Marth C; Kim JW; Raspagliesi F; Lampe B; Aletti G; Meier W; Cibula D; Mustea A; Mahner S; Runnebaum IB; Schmalfeldt B; Burges A; Kimmig R; Scambia G; Greggi S; Hilpert F; Hasenburg A; Hillemanns P; Giorda G; von Leffern I; Schade-Brittinger C; Wagner U; du Bois A
N Engl J Med; 2019 Feb; 380(9):822-832. PubMed ID: 30811909
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Morrison J; Thoma C; Goodall RJ; Lyons TJ; Gaitskell K; Wiggans AJ; Bryant A
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007927. PubMed ID: 30321910
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.
Oshita T; Itamochi H; Nishimura R; Numa F; Takehara K; Hiura M; Tanimoto H; Noma J; Hayase R; Murakami A; Fujimoto H; Kanamori Y; Kitada F; Shitsukawa K; Nagaji M; Minagawa Y; Fujiwara M; Kigawa J
Int J Clin Oncol; 2013 Dec; 18(6):1107-13. PubMed ID: 23073623
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Winter-Roach BA; Kitchener HC; Dickinson HO
Cochrane Database Syst Rev; 2009 Jan; (1):CD004706. PubMed ID: 19160239
[TBL] [Abstract][Full Text] [Related]
37. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis.
Li D; Ding CY; Qiu LH
Gynecol Oncol; 2015 Nov; 139(2):355-62. PubMed ID: 26232517
[TBL] [Abstract][Full Text] [Related]
38. The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer.
Abe A; Furumoto H; Irahara M; Ino H; Kamada M; Naka O; Sasaki M; Kagawa T; Okitsu O; Kushiki N
J Obstet Gynaecol Res; 2010 Oct; 36(5):1023-30. PubMed ID: 21058437
[TBL] [Abstract][Full Text] [Related]
39. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials.
Jiang Y; Sun X; Kong B; Jiang J
Medicine (Baltimore); 2018 Aug; 97(34):e11920. PubMed ID: 30142803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
